Biogen beats estimates on Spinraza sales, raises forecast
Biogen Inc reported a better-than-expected quarterly profit on Tuesday and raised its forecast for 2018 adjusted earnings, driven by strong demand for its spinal muscular atrophy drug Spinraza, sending its shares up 3...
Read More